Ibrutinib was approved to treat mantle cell lymphoma by the US Food and Drug Administration (FDA) on an “accelerated” basis. In clinical studies, tumors responded to this medicine.
However, it has not been shown that ibrutinib can improve symptoms or lengthen survival time in people with this type of lymphoma. Ibrutinib may also be used for purposes not listed in this medication guide.
https://morlancancerpharmacy.com/product/buy-imbruvica-online/
